Live Chat
Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    editors, Eric C. Eichenwald, Anne R. Hansen, Camilia R. Martin, Ann R. Stark.
    Contents:
    Sect. 1: Prenatal assessment and conditions
    Sect. 2: Assessment and treatment in the immediate postnatal period
    Sect. 3: General newborn condition
    Sect. 4: Fluid electrolytes nutrition, gastrointestinal, and renal issues
    Pt. 5: Respiratory disorders
    Pt. 6: Cardiovascular disorders
    Pt. 7: Hematologic disorders
    Pt. 8: Infectious diseases
    Pt. 9: Neurologic disorders
    Pt. 10: Bone conditions
    Pt. 11: Metabolism
    Pt. 12: Endocrinology
    Pt. 13: Surgery
    Pt. 14: Dermatology
    Pt. 15: Vascular anomalies
    Pt. 16: Auditory and ophthalmologic disorders
    Pt. 17: Common neonatal procedures
    Pt. 18: Pain and stress control.
    Digital Access
    Provider
    Version
    LWW Health Library
    2017
    Ovid
    2017
    Print Access Request
    Location
    Version
    Call Number
    Items
    Books: General Collection (Downstairs)
    2017
    RJ254 .J63 2017
    1
  • Article
    Walker BR, Ballard IM, Gold JA.
    J Int Med Res. 1977;5(2):85-90.
    Mazindol is chemically unrelated to the phenethylamines and has not shown the side-effects or abuse potential of the amphetamine anorectics. To further define its potential for causing weight loss, a six-week double-blind placebo controlled study was undertaken in four centres. A common protocol was used except in one centre, behavioural modification also was employed, whereas in the other centres, no additional measures were used to cause weight loss. Two hundred and forty-five obese patients were assigned randomly to two mazindol groups and one placebo group in each centre. Ninety-eight and forty patients receiving mazindol and placebo respectively completed the protocol. The conclusions were: (a) no significant clinical or laboratory abnormalities occurred from mazindol therapy, (b) the placebo therapy patients did not lose weight without behavioural modification, (c) the placebo therapy group had a higher drop-out rate compared to the mazindol therapy group attributable to the patients' dissatisfaction with failure to lose weight, (d) mazindol therapy without behavioural modification and behavioural modification alone both resulted in a statistically significant mean weight loss of 1 pound/patient/week and (e) mazindol plus behavioural modification resulted in a greater mean weight loss of 1/2 pound/patient/week than with behavioural modification alone. Hence, mazindol is of value in the initial therapy of obesity.
    Digital Access Access Options